All patients
age >= 55 yr age >= 65 yr critical disease
convalescent plasma treatment in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Bennett-Guerrero, 2021 0.86 [0.24; 3.11]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
0.81 [0.60 ; 1.08 ] Bennett-Guerrero, 2021, CONTAIN COVID-19, 2021, O’Donnell, 2021, PlasmAr, 2020 4 0% 1,571 moderate not evaluable deathsdetailed results Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
CCAP-2, 2021 2.03 [0.61; 6.77]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
Libster, 2020 0.50 [0.09; 2.71]
NCT04442191, 2021 0.11 [0.00; 143.68]
O’Donnell, 2021 0.47 [0.21; 1.06]
PlasmAr, 2020 0.93 [0.47; 1.85]
0.86 [0.65 ; 1.13 ] Baldeon, 2022, Bennett-Guerrero, 2021, CCAP-2, 2021, CONTAIN COVID-19, 2021, Libster, 2020, NCT04442191, 2021, O’Donnell, 2021, PlasmAr, 2020 8 0% 2,048 moderate not evaluable deaths (time to event analysis only)detailed results Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
PlasmAr, 2020 0.93 [0.47; 1.85]
1.01 [0.59 ; 1.72 ] Baldeon, 2022, Bennett-Guerrero, 2021, PlasmAr, 2020 3 0% 566 low not evaluable clinical deteriorationdetailed results CONTAIN COVID-19, 2021 0.94 [0.75; 1.18]
Libster, 2020 0.52 [0.29; 0.94]
0.75 [0.42 ; 1.31 ] CONTAIN COVID-19, 2021, Libster, 2020 2 71% 1,101 moderate not evaluable clinical improvementdetailed results Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
1.04 [0.80 ; 1.37 ] Bennett-Guerrero, 2021, O’Donnell, 2021, PlasmAr, 2020 3 3% 630 low not evaluable clinical improvement (28-day)detailed results Bennett-Guerrero, 2021 1.02 [0.25; 4.20]
O’Donnell, 2021 1.38 [0.73; 2.61]
1.31 [0.73 ; 2.34 ] Bennett-Guerrero, 2021, O’Donnell, 2021 2 0% 297 low not evaluable clinical improvement (time to event analysis only)detailed results Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
1.07 [0.87 ; 1.32 ] Bennett-Guerrero, 2021, O’Donnell, 2021, PlasmAr, 2020 3 0% 631 low not evaluable mechanical ventilationdetailed results O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
1.03 [0.53 ; 2.00 ] O’Donnell, 2021, PlasmAr, 2020 2 0% 556 low not evaluable ICU admissiondetailed results Libster, 2020 0.33 [0.07; 1.58]
0.33 [0.07 ; 1.58 ] Libster, 2020 1 0% 160 NA not evaluable serious adverse eventsdetailed results O’Donnell, 2021 0.64 [0.35; 1.17]
PlasmAr, 2020 1.40 [0.78; 2.51]
0.95 [0.44 ; 2.05 ] O’Donnell, 2021, PlasmAr, 2020 2 70% 552 low not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-03-29 14:41 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 538,957
- roots T: 290